NorthWest Biotherapeutics Inc (NWBO)

[Hopeforthefuture3]

Guzzi62, If you want to learn about gbm and the dcvax treatment there are a lot of really good links you can find after the posts. I suggest you watch some of the videos and read some of the papers. Be careful about counting on some of the things you read from the posts without back up. One you seem to like claimed NWBO did not receive a RFI (request for information) as they did not issue an 8-k to that effect. A RFI is a normal part of the UK approval process and virtually never requires an 8-k. This same poster since I put him onto the national library of medicine (look up pubmed with google) and told him to type in dendritic cells AND cancer (you will find over 30,000 published papers) has been on a marathon claiming everything is dcvax. The research has been ongoing for years from many institutions and some is truly dcvax but most of those 30,000 works are not dcvax but one has to have some understanding to recognize the difference. I believe dcvax does truly help some gbm sufferers but not all. Ask yourself why if dcvax is the only answer then in the most recent UCLA spore grant to research treatments for gbm only SPORE program 1 includes dcvax? Program 2 is for targeted therapy such as EGFR led by Tim Cloughsey and program 3 is trying to overcome radiation resistance led by Phioanah Nghiemphu. You can look up all of these smart dedicated physicians (Liau, Prins, Cloughsey, and Nghiemphu) with google and search on videos and they all have good presentations with various levels of technical knowledge needed and see what they are working on, the success they have had and the limitations.
Start by reading the paper at this link, it is from early and successful work done by Liau and Prins - I found it to be very interesting many years ago and still find it the same today
Clin Cancer Res
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Clin Cancer Res. 2010 Dec 6;17(6):1603–1615. doi: 10.1158/1078-0432.CCR-10-2563
Gene expression profile correlates with T cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
Robert M Prins 1,4,5,*, Horacio Soto 1, Vera Konkankit 1, Sylvia K Odesa 1, Ascia Eskin 2, William H Yong 3, Stanley F Nelson 2,4,5, Linda M Liau


https://pmc.ncbi.nlm.nih.gov/articles/PMC3071163/

The mesenchymal gene expression signature is defined by overexpression of many inflammatory-associated genes. Thus, we hypothesized that there might be a difference in the clinical outcome of patients on our trial that could be linked to the local microenvironment of the original tumor.